MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

Journal of Neurology

Volumn 260, Issue 4, 2013, Pages 1136-1146

  Comi, Giancarlo ^a   Cook, Stuart D ^b   Giovannoni, Gavin ^c   Rammohan, Kottil ^d   Rieckmann, Peter ^e   Sørensen, Per Soelberg ^f   Vermersch, Patrick ^g   Hamlett, Anthony C ^h   Viglietta, Vissia ^h   Greenberg, Steven J ^h  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f University of Copenhagen   (Denmark)

^g UNIV LILLE   (France)

^h MERCK SERONO S A   (Switzerland)

Author keywords

Cladribine tablets; CLARITY study; Disease modifying therapy; MRI outcome measures; Relapsing remitting multiple sclerosis

Indexed keywords

CLADRIBINE; GADOLINIUM; PLACEBO;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SHORT COURSE THERAPY; TABLET;

ANALYSIS OF VARIANCE; BRAIN; CLADRIBINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TABLETS; TREATMENT OUTCOME;

EID: 84876459085     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6775-0     Document Type: Article

References (40)

1. Arnold DL (2007) The place of MRI in monitoring the individual MS patient. J Neurol Sci 259:123-127
2. Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Poppe P, de VM, Lasri F, Bauer L, Dahms S, Wagner K, Pohl C, Sandbrink R (2007) Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol 64:1292-1298
3. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158-164
4. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415
5. Comi G (2010) Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis. Neurol Sci 31:S261-S264
6. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371:2085-2092
7. Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Soelberg Sørensen P, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg S (2011) Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (cladribine tablets treating multiple sclerosis orally) study. Mult Scler 17:578-593
8. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH (2008) Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131:808-817
9. Gauthier SA, Mandel M, Guttmann CR, Glanz BI, Khoury SJ, Betensky RA, Weiner HL (2007) Predicting short-term disability in multiple sclerosis. Neurology 68:2059-2065
10. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362:416-426
11. Giovannoni G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Hamlett A, Viglietta V, Greenberg S (2011) Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post hoc and subgroup analysis. Lancet Neurol 10:329-337
12. Gold R, Kappos L, Bar-Or A, Arnold D, Giovannoni G, Selmaj K, Yang M, Dawson K, Bochum D, Lodz P (2011) Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial. N Engl J Med 367:1098-1107
13. Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW (2009) GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 72:806-812
14. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F (2001) Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 57:1969-1975
15. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387-401
16. Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart F, Sartori E, Wardi R, Wiertlewski S, Edan G (2011) Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 308:98-102
17. Leist TP, Vermersch P (2007) The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 23:2667-2676
18. Leist TP, Weissert R (2011) Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 34:28-35
19. Lim SY, Constantinescu CS (2010) Current and future disease-modifying therapies in multiple sclerosis. Int J Clin Pract 64:637-650
20. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag BM (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis [the REbif vs Glatiramer Acetate in Relapsing MS Disease (REGARD) study]: a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7:903-914
21. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, Lublin FD, Paty DW, Reingold SC, Simon J (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 39:6-16
22. Miller DH, Soon D, Fernando KT, Macmanus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68:1390-1401
23. Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP, Kappos L, Miller DH, Montalban X, Lanius V, Sandbrink R, Barkhof F (2009) Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol 66:1345-1352
24. Mostert JP, Koch MW, Steen C, Heersema DJ, De Groot JC, De Keyser J (2010) T2 lesions and rate of progression of disability in multiple sclerosis. Eur J Neurol 17:1471-1475
25. Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer L, Sandbrink R, Kappos L, Uitdehaag BM (2009) MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurol 9:19
26. O'Riordan JI, Thompson AJ, Kingsley DP, Macmanus DG, Kendall BE, Rudge P, McDonald WI, Miller DH (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121:495-503
27. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
28. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C (2009) One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 16:1202-1209
29. Rammohan K, Vermersch P, Comi G, Giovannoni G, Rieckmann P, Soelberg Sørensen P, Chang P, Hamlett A, Musch B, Verjee R, Greenberg S (2009) Cladribine tablets produce sustained improvements in relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, 9-12 September 2009 (abstract P818, p S249)
30. Rieckmann P, Comi G, Cook S, Giovannoni G, Rammohan K, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Viglietta V, Musch B, Greenberg S (2009) Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96 week, phase III, double-blind, placebo-controlled CLARITY study. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, 9-12 September 2009 (abstract P816, p S248-S249)
31. Rudick RA, Lee JC, Simon J, Fisher E (2006) Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 60:236-242
32. Ruggieri M, Avolio C, Livrea P, Trojano M (2007) Glatiramer acetate in multiple sclerosis: a review. CNS Drug Rev 13:178-191
33. Scott TF, Schramke CJ, Novero J, Chieffe C (2000) Short-term prognosis in early relapsing-remitting multiple sclerosis. Neurology 55:689-693
34. Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, Frank JA, Grossman R, Paty DW, Radue EW, Wolinsky JS (2006) Standardized MR imaging protocol for multiple sclerosis: consortium of MS centers consensus guidelines. Am J Neuroradiol 27:455-461
35. Soelberg Sørensen P, Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, Vermersch P, Chang P, Hamlett A, Viglietta V, Verjee R, Musch B, Greenberg S (2009) Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis (RRMS) in the 96 week, phase III, double-blind, placebo-controlled CLARITY study. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, 9-12 September 2009 (abstract P472, p S137)
36. Stadelmann C (2011) Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr Opin Neurol 24:224-229
37. Tintore M (2009) New options for early treatment of multiple sclerosis. J Neurol Sci 277:S9-S11
38. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP (2007) New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 61:300-306
39. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP (2009) Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. J Neurol Sci 286:109-113
40. Vermersch P, Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, Soelberg Sørensen P, Chang P, Hamlett A, Musch B, Verjee R, Greenberg S (2009) Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, 9-12 September 2009 (abstract P817, p S249)